Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
Contacts:PHILADELPHIA, May 29, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 11:00 a.m. ET in New York, NY.
費城，2024年5月29日（GLOBE NEWSWIRE）——專注於開發和推出首款專爲自身免疫性疾病患者設計的治療性靶向細胞療法的臨床階段生物技術公司Cabaletta Bio, Inc.（納斯達克股票代碼：CABA）今天宣佈，首席執行官史蒂芬·尼希特伯格醫學博士將於2024年6月5日星期三參加傑富瑞全球醫療保健會議的爐邊談話美國東部時間上午 11:00 在紐約州紐約
A live webcast of the presentation will be available on the News and Events section of the Company's website at . Replays will be available on the website for 30 days.
該演示文稿的網絡直播將在公司網站的 “新聞和活動” 欄目上播出 。重播將在網站上播放 30 天。
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in the RESET (REstoring SElf-Tolerance) clinical trials in systemic lupus erythematosus, myositis, systemic sclerosis and generalized myasthenia gravis and in the RESET-PV sub-study within the DesCAARTes clinical trial in pemphigus vulgaris, along with the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis. The expanding CABA platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio's headquarters and labs are located in Philadelphia, PA.
關於 Cabaletta Bio
Cabaletta Bio（納斯達克股票代碼：CABA）是一家臨床階段的生物技術公司，專注於發現和開發工程化T細胞療法，這些療法有可能爲自身免疫性疾病患者提供深入、持久、也許是治癒性的治療。CABA 平台包括兩種策略：CARTA（用於自身免疫的嵌合抗原受體 T 細胞）策略，其中 CABA-201（一種完全含有 4-1BB 的人類 CD19-CAR T）作爲主要候選產品，正在系統性紅斑狼瘡、肌炎、系統性硬化和全身性重症肌無力的 RESET（恢復自我耐受）臨床試驗以及該研究中的 RESET-PV 子研究中進行評估 Descaartes尋常型天皰瘡臨床試驗，以及CAART（嵌合自身抗體受體T細胞）策略，分爲多個臨床階段候選藥物，包括治療尋常型粘膜天皰瘡的 DSG3-CAART 和治療與馬斯克相關的重症肌無力的 Musk-CAART。不斷擴大的CABA平台旨在開發潛在的治療療法，爲患有各種自身免疫性疾病的患者提供深層而持久的反應。Cabaletta Bio的總部和實驗室位於賓夕法尼亞州費城。
Contacts:
聯繫人：
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
Anup Marda
首席財務官
investors@cabalettabio.com
William Gramig
Precision AQ
william.gramig@precisionaq.com
威廉·格拉米格
精度 AQ
william.gramig@precisionaq.com
譯文內容由第三人軟體翻譯。